Recognising withdrawal and complications #
A reduction in sustained heavy alcohol exposure may produce tremor, sweating, anxiety, nausea, insomnia and autonomic activation. Withdrawal can occur while alcohol remains detectable. Distinguish uncomplicated withdrawal, withdrawal seizures and delirium tremens; an apparently modest questionnaire total cannot exclude later complications.
Initial assessment and care setting #
Document last intake, usual pattern, previous seizures or delirium, concurrent sedative dependence, current medicines and available support. Examine consciousness, orientation, vital signs, hydration and injury. Hospital care is indicated for complicated withdrawal or substantial likelihood of seizures or delirium; frailty, cognitive impairment and limited support lower the admission threshold.
Do not attribute every abnormality to withdrawal #
| Finding | Alternative to assess |
|---|---|
| Confusion or reduced consciousness | Head injury, infection, hypoglycaemia, intoxication or hepatic encephalopathy. |
| Seizure | Other epilepsy, metabolic disturbance or intracranial disease, particularly with an atypical history. |
| Eye-movement abnormality or gait impairment | Wernicke encephalopathy may coexist with withdrawal. |
Investigations linked to examination #
Measure bedside glucose and assess oxygenation promptly. Blood count, electrolytes, renal and liver function inform the differential and prescribing context; magnesium and phosphate are especially relevant with malnutrition. ECG, infection studies, neuroimaging and toxicology should answer a specific suspected complication. Obtain collateral rather than assuming an unreliable history proves a benign withdrawal course.
Withdrawal, nutrition and supportive care #
Use an agreed benzodiazepine protocol with trained staff and repeated assessment. Symptom-triggered treatment requires a setting capable of the required observation; a fixed schedule still needs reassessment for both undertreatment and oversedation. Correct fluids and nutrition appropriately, provide thiamine, and manage concurrent illness. The regimen below is a supervised guideline example, not an automatic response to a website score.
Doses & prescribing #
Each prescribing record identifies its population and source jurisdiction; international labeling does not establish Indian approval. The clinician selects treatment after assessment.
Chlordiazepoxide
Supervised alcohol withdrawal: ASAM sample symptom-triggered regimen
Adults · Oral capsules/tablets · Oral · US ASAM supervised protocol example; not an Indian product-label claim.
- Starting dose
- ASAM example: 25–100 mg orally when CIWA-Ar is ≥10; clinical severity and vulnerability determine the selected dose.
- Titration
- Example interval every 4–6 hours, with reassessment and additional doses only under the supervising protocol.
- Treatment range / target
- 25–100 mg per administration in this sample schedule.
- Maximum / limits
- No universal daily maximum is defined by this sample; escalating need or oversedation requires senior review, not unrestricted repeat dosing.
- Trial & duration
- Acute withdrawal only; fixed-dose examples taper over 3–5 days.
- Monitoring
- Trained observation of symptoms, alertness and respiration; reassess before dosing.
- Population & organ-function adjustments
- Reduce exposure or choose an alternative when hepatic impairment or frailty increases accumulation risk.
- Important cautions
- Not a home self-dosing schedule. CIWA-Ar is unsuitable for directing doses in delirium or unreliable communication.
Thiamine
Suspected or established Wernicke encephalopathy in hospital
Adults · Parenteral thiamine preparation; check product concentration and infusion instructions · Intravenous · UK Department of Health and Social Care hospital guidance.
- Starting dose
- 300–500 mg three times daily for 3–5 days with daily review.
- Titration
- If still symptomatic after the first 5 days, 300–500 mg once daily for another 3–5 days, then while improvement continues.
- Treatment range / target
- Treatment schedule above; distinct from prophylaxis.
- Maximum / limits
- 500 mg per administration within the cited treatment schedule.
- Trial & duration
- Parenteral course followed by oral supplementation.
- Monitoring
- Clinical response, magnesium and infusion reactions; anaphylaxis treatment facilities and trained staff available.
- Population & organ-function adjustments
- Correct magnesium deficiency if present; investigate other causes of persistent confusion.
- Important cautions
- This is the UK hospital guideline treatment schedule, not the lower-dose prevention schedule.
Escalation and complications #
Persistent severe symptoms require reassessment of diagnosis, drug delivery and monitoring capability. Withdrawal seizures require acute medical treatment and review of the withdrawal regimen; phenytoin is not treatment for alcohol-withdrawal seizures. Delirium tremens needs urgent specialist management. Antipsychotics must not replace adequate benzodiazepine treatment for withdrawal delirium.
After the acute episode #
End the withdrawal benzodiazepine course when clinically appropriate and provide a direct transition to AUD treatment. Explain that restarting drinking and stopping again can create another withdrawal episode. Record what was effective, the total sedative exposure, complications and the next named service.
Liver disease, frailty and pregnancy #
Long-acting agents can accumulate with impaired hepatic clearance. Advanced liver disease requires specialist involvement and a medicine with an appropriate metabolic profile rather than a simple age-only dose reduction. Pregnancy, concurrent sedative withdrawal and severe respiratory disease require an individually supervised plan.
What to monitor #
Trend alertness, respiratory status, pulse, blood pressure, temperature, hydration, oral intake and withdrawal symptoms. Investigate a deteriorating conscious level rather than automatically adding sedative. Document the ability to participate in assessment and whether the selected scale remains interpretable.
Common acute-care errors #
Do not delay treatment of hypoglycaemia while arranging thiamine. Do not use oral vitamin treatment as a substitute for parenteral treatment of suspected Wernicke encephalopathy. An isolated improvement in tremor does not establish medical stability or discharge readiness.
Assessment tools #
Choose the instrument for its intended purpose; interpretation accompanies the linked tool.
Patient discussion #
Open a plain-language explanation
Withdrawal can become medically serious. The clinician considers past withdrawal, current symptoms and physical health when arranging supervision.
References · 4
- ASAM alcohol withdrawal guideline · United States · Checked 2026-10-26 · Supports: Recognising withdrawal and complications; Withdrawal, nutrition and supportive care; After the acute episode; What to monitor; Common acute-care errors; Chlordiazepoxide — Supervised alcohol withdrawal: ASAM sample symptom-triggered regimen (Oral capsules/tablets)
- NICE CG100: alcohol-related physical complications · United Kingdom · Checked 2026-10-26 · Supports: Initial assessment and care setting; Withdrawal, nutrition and supportive care; Escalation and complications; Liver disease, frailty and pregnancy
- UK alcohol guidelines: acute hospitals · United Kingdom · Checked 2026-10-26 · Supports: Investigations linked to examination; Escalation and complications; Common acute-care errors; Thiamine — Suspected or established Wernicke encephalopathy in hospital (Parenteral thiamine preparation; check product concentration and infusion instructions)
- WHO: withdrawal management in closed settings · WHO; closed institutional settings · Checked 2026-10-26 · Supports: Do not attribute every abnormality to withdrawal; Investigations linked to examination; Liver disease, frailty and pregnancy